| Previous close | 36.02 |
| Open | 36.37 |
| Bid | 36.10 x 1400 |
| Ask | 36.63 x 1800 |
| Day's range | 35.76 - 36.33 |
| 52-week range | 27.88 - 40.97 |
| Volume | 20,755,537 |
| Avg. volume | 27,911,012 |
| Market cap | 201.437B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | 14.35 |
| EPS (TTM) | 2.53 |
| Earnings date | 27 Oct 2020 |
| Forward dividend & yield | 1.52 (4.19%) |
| Ex-dividend date | 30 Jul 2020 |
| 1y target est | 41.79 |
- Editor's pickYahoo Finance
Coronavirus update: US death toll tops 200K as Europe outlook darkens; FDA adds teeth to vaccine process
The U.S. marked a grim milestone in the coronavirus pandemic, with more than 200,000 deaths reported Tuesday, even as optimism continues to rise over a vaccine.
- Business Wire
FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. XALKORI received Breakthrough Therapy designation (BTD) for the ALK-positive ALCL indication in May 2018 and if approved, would be the first biomarker-driven therapy for this type of pediatric lymphoma. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is January 2020.
- Motley Fool
2 High-Yield Dividend Stocks I'd Buy Right Now
One way to maximize your potential returns is to invest in stocks that pay dividends. The two stocks listed here, Pfizer (NYSE: PFE) and Verizon (NYSE: VZ), not only still pay dividends, they've also been increasing them over the years. Healthcare giant Pfizer is an attractive investment for multiple reasons.
